Skip to main content

At the LDRI, our researchers contribute actively to help in managing DDIs in SARS-CoV-2 infected patients.

ldri | Bruxelles Woluwe

ldri
6 May 2020, modified on 13 December 2024
  1. “Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions”. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188032/ Laure Elens, PhD, Loralie J. Langman, PhD, Dennis A. Hesselink, MD, PhD, Stein Bergan, PhD, Dirk Jan A.R. Moes, MD, PhD, Mariadelfina Molinaro, MScBiol, Raman Venkataramanan, PhD, and Florian Lemaitre, PhD
  2. https://sfpt-fr.org/images/covid19/IAM_et_traitements_du_COVID.pdf, Florian Lemaitre, Caroline Solas, Matthieu Grégoire, Laurence Lagarce, Laure Elens, Elisabeth Polard, Béatrice Saint-Salvi, Agnès Sommet, Michel Tod et Chantal Le Guellec on behalf of SFPT and IATDMCT